01-2031
|
A randomized, double-blind, double-dummy, parallel-group
A randomized, double-blind, double-dummy, parallel-group
|
06-2029
|
A Randomized, Double-blind, Phase 3 Study Comparing Effi
A Randomized, Double-blind, Phase 3 Study Comparing Effi
|
05-2029
|
An Interventional, Phase 3 Extension Study to Investigat
An Interventional, Phase 3 Extension Study to Investigat
|
04-2029
|
A 2-Part, Multicenter, Randomized, Blinded, Active-Contr
A 2-Part, Multicenter, Randomized, Blinded, Active-Contr
|
02-2029
|
Retrospective Evaluation of Infusion Tolerability: BRIUM
Retrospective Evaluation of Infusion Tolerability: BRIUM
|
10-2028
|
Master Protocol of Two Independent, Randomized, Double-B
Master Protocol of Two Independent, Randomized, Double-B
|
05-2028
|
A Phase 2, Randomized Study of Pirtobrutinib versus Plac
A Phase 2, Randomized Study of Pirtobrutinib versus Plac
|
04-2028
|
Evaluating the maintenance of efficacy when transitionin
Evaluating the maintenance of efficacy when transitionin
|
02-2028
|
Performance and safety of a digital tool for the unsuper
Performance and safety of a digital tool for the unsuper
|
03-2027
|
A Phase 3, Randomized, Double-Blind Efficacy and Safety
A Phase 3, Randomized, Double-Blind Efficacy and Safety
|
09-2026
|
SPHERES NMOSD Registry
SPHERES NMOSD Registry
|
05-2026
|
A Phase 1 Study of the Safety and Tolerability of Single
A Phase 1 Study of the Safety and Tolerability of Single
|
05-2026
|
A randomized, open label, multi-center, active-comparato
A randomized, open label, multi-center, active-comparato
|
03-2026
|
A MULTICENTER, SINGLE-ARM, OPEN-LABEL, EXTENSION, ROLLOV
A MULTICENTER, SINGLE-ARM, OPEN-LABEL, EXTENSION, ROLLOV
|
10-2025
|
A Phase III Multicenter, Randomized, Double-Blind, Doubl
A Phase III Multicenter, Randomized, Double-Blind, Doubl
|
10-2025
|
PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTRO
PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTRO
|
10-2025
|
A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONT
A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONT
|
08-2025
|
A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS
A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS
|
06-2025
|
Protocol #EFC16035
Protocol #EFC16035
|
06-2025
|
Protocol #EFC16645
Protocol #EFC16645
|
05-2025
|
Protocol #EFC16033
Protocol #EFC16033
|
12-2024
|
Protocol #TG1101-RMS303
Protocol #TG1101-RMS303
|
12-2024
|
Protocol #TREATMS
Protocol #TREATMS
|
12-2024
|
Protocol #CBAF312AUS02
Protocol #CBAF312AUS02
|
11-2024
|
AGNOS: An 18-month, Open-label, Multi-Center Study to As
AGNOS: An 18-month, Open-label, Multi-Center Study to As
|
10-2024
|
Traditional versus Early Aggressive Therapy for Multiple
Traditional versus Early Aggressive Therapy for Multiple
|
06-2024
|
NMSS Multiple Sclerosis Clinical Care Physician Fellowsh
NMSS Multiple Sclerosis Clinical Care Physician Fellowsh
|
05-2024
|
A MULTIPLE-CENTER, NON-RANDOMIZED, OPEN-LABEL, ADAPTIVE,
A MULTIPLE-CENTER, NON-RANDOMIZED, OPEN-LABEL, ADAPTIVE,
|
04-2024
|
A Phase III, Non-Inferiority, Randomized, Open-Label, Pa
A Phase III, Non-Inferiority, Randomized, Open-Label, Pa
|
03-2024
|
An Open-Label Phase 1 Study to Evaluate the Safety of AT
An Open-Label Phase 1 Study to Evaluate the Safety of AT
|
03-2024
|
A Phase 2 Double-Blind, Randomized, Placebo-Controlled S
A Phase 2 Double-Blind, Randomized, Placebo-Controlled S
|
02-2024
|
Protocol #DRI15928
Protocol #DRI15928
|
01-2024
|
Protocol #OMB157G2399
Protocol #OMB157G2399
|
01-2024
|
Protocol #CBAF312AUS02
Protocol #CBAF312AUS02
|
11-2023
|
Protocol #101MS329
Protocol #101MS329
|
09-2023
|
Protocol #OMB157G2102
Protocol #OMB157G2102
|
08-2023
|
COVID-19 Neuro Databank/Biobank "NeuroCOVID Study"
COVID-19 Neuro Databank/Biobank "NeuroCOVID Study"
|
08-2023
|
Protocol #ML29972
Protocol #ML29972
|
05-2023
|
Protocol #CD-IA-MEDI-551-1155
Protocol #CD-IA-MEDI-551-1155
|
05-2023
|
Protocol #MS200527_0082
Protocol #MS200527_0082
|
04-2023
|
Protocol #OMB157G23101
Protocol #OMB157G23101
|
02-2023
|
Protocol #GN41791
Protocol #GN41791
|
02-2023
|
Protocol #GWSP18023
Protocol #GWSP18023
|
01-2023
|
Protocol #PRIMEMS
Protocol #PRIMEMS
|
11-2022
|
Protocol #LPS13649
Protocol #LPS13649
|
10-2022
|
Protocol #215MS202
Protocol #215MS202
|
08-2022
|
NMSS Multiple Sclerosis Clinical Care Physician Fellowsh
NMSS Multiple Sclerosis Clinical Care Physician Fellowsh
|
08-2022
|
Protocol #MD1003CT2016-01MS-SPI2
Protocol #MD1003CT2016-01MS-SPI2
|
06-2022
|
Protocol #LTS16004
Protocol #LTS16004
|
04-2022
|
Protocol #CN41144
Protocol #CN41144
|
02-2022
|
Protocol #MS700568_0078
Protocol #MS700568_0078
|
02-2022
|
Protocol #MS700568_0079
Protocol #MS700568_0079
|
01-2022
|
Protocol #MA30143
Protocol #MA30143
|
01-2022
|
Protocol #OBS13434
Protocol #OBS13434
|
06-2021
|
Protocol #OBS14527
Protocol #OBS14527
|
04-2021
|
Protocol #ARISE
Protocol #ARISE
|
03-2021
|
Protocol #TREATMS
Protocol #TREATMS
|
03-2021
|
Protocol #MN39159
Protocol #MN39159
|
02-2021
|
Protocol #MN30035
Protocol #MN30035
|
02-2021
|
Protocol #205MS305
Protocol #205MS305
|
09-2020
|
Protocol #BN29739
Protocol #BN29739
|
09-2020
|
Protocol #109MS310
Protocol #109MS310
|
06-2020
|
Protocol #AC-058B303
Protocol #AC-058B303
|
06-2020
|
Protocol #TG1101-RMS301
Protocol #TG1101-RMS301
|
04-2020
|
Protocol #AC-058B301
Protocol #AC-058B301
|
02-2020
|
Protocol #MNK4069
Protocol #MNK4069
|
10-2019
|
Protocol #Prime
Protocol #Prime
|
06-2019
|
Protocol #OS440PKP06
Protocol #OS440PKP06
|
05-2019
|
Protocol #MS200136
Protocol #MS200136
|
05-2019
|
Protocol #COMB157G2302
Protocol #COMB157G2302
|
02-2019
|
Protocol #EFC15824
Protocol #EFC15824
|
04-2018
|
Protocol #MS Relapses
Protocol #MS Relapses
|
03-2018
|
Protocol #DRI13839
Protocol #DRI13839
|
07-2017
|
Protocol #109MS412
Protocol #109MS412
|
06-2017
|
The University of South Florida Multiple Sclerosis Fello
The University of South Florida Multiple Sclerosis Fello
|
06-2017
|
Protocol #218MS305
Protocol #218MS305
|
03-2017
|
Protocol #Teriflunomide
Protocol #Teriflunomide
|
02-2017
|
Protocol #109MS401/ESTEEM
Protocol #109MS401/ESTEEM
|
01-2017
|
Protocol #US-BGT-13-10458
Protocol #US-BGT-13-10458
|
01-2017
|
Protocol #EMR200559-006
Protocol #EMR200559-006
|
11-2016
|
Protocol #CD-IA-MEDI-551-1102
Protocol #CD-IA-MEDI-551-1102
|
10-2016
|
Protocol #LTS13840
Protocol #LTS13840
|
08-2016
|
Protocol #Cerebrotendinous Xanthomatosis
Protocol #Cerebrotendinous Xanthomatosis
|
07-2016
|
Protocol #CLR_09_21
Protocol #CLR_09_21
|
07-2016
|
Protocol #CLR_11_04
Protocol #CLR_11_04
|
07-2016
|
Protocol #109MS404
Protocol #109MS404
|
06-2016
|
Protocol #109MS403
Protocol #109MS403
|
05-2016
|
Protocol #BAF312A2304
Protocol #BAF312A2304
|
01-2016
|
Protocol #EMR200559-005
Protocol #EMR200559-005
|
01-2016
|
Protocol #RPC01-201
Protocol #RPC01-201
|
01-2016
|
Protocol# 101-MS-402 TYGRIS
Protocol# 101-MS-402 TYGRIS
|
12-2015
|
Protocol # WA21093
Protocol # WA21093
|
05-2015
|
Protocol#109MS303
Protocol#109MS303
|
02-2015
|
Protocol #CAMMS03409
Protocol #CAMMS03409
|
01-2015
|
Protocol# 101MS326
Protocol# 101MS326
|
06-2014
|
Questcor Training Services
Questcor Training Services
|
12-2012
|
Protocol# WA21092
Protocol# WA21092
|
10-2012
|
Protocol#101JC402
Protocol#101JC402
|